Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Traumatic brain injury: pathophysiology and neuroprotective therapy (CROSBI ID 689795)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | domaća recenzija

Pilipović, Kristina ; Dolenec, Petra ; Rajič Bumber, Jelena ; Janković, Tamara ; Gržeta, Nika ; Župan, Željko ; Križ, Jasna ; Župan, Gordana Traumatic brain injury: pathophysiology and neuroprotective therapy // 9. Hrvatski kongres farmakologije s međunarodnim sudjelovanjem - zbornik sažetaka. Zagreb: Hrvatsko društvo farmakologa, 2019. str. 53-54

Podaci o odgovornosti

Pilipović, Kristina ; Dolenec, Petra ; Rajič Bumber, Jelena ; Janković, Tamara ; Gržeta, Nika ; Župan, Željko ; Križ, Jasna ; Župan, Gordana

engleski

Traumatic brain injury: pathophysiology and neuroprotective therapy

Traumatic brain injury (TBI) is a major cause of death and long-term disability, especially in previously healthy young people. It is also associated with increased posttraumatic incidence of different diseases and disturbances such as neurodegenerative, psychiatric, cognitive and sleep disorders, systemic metabolic and neuroendocrine dysregulations, sexual dysfunction, etc., many of them lifelong. The most frequent causes of single TBI are falls and motor vehicle accidents while the repetitive form is more often associated with contact sports, domestic spousal violence, child abuse or blast injuries. Because of all the above mentioned, TBI presents a significant public health problem all over the world. It is a complex continuous disease process that includes different events with subsequent brain tissue damage. Although numerous preclinical and clinical studies were done in order to clarify the pathophysiology of the brain trauma, all the mechanisms involved in the brain structures’ damage still remain unknown. Today's therapy of TBI patients is supportive and symptomatic. Clinically effective pharmacological neuroprotective therapy for TBI has not yet been established. Therefore, development of novel pharmacological treatment options is of the highest priority. Today, special attention is on multifunctional drugs that affect different processes of brain damage in TBI. In this talk, an overview of current knowledge on the pathophysiology of single and repetitive mild TBI as well as on different neuroprotective therapeutic strategies, including our recent results in this field, will be presented. This work was supported in parts by Croatian Science Foundation, project IP-2016-064602 to Ž.G., University of Rijeka, projects uniri- biomed-18-204 to Ž.G. and uniri-biomed-18-199 to P.K., and Ministry of Science, Education, and Sports of the Republic of Croatia, project 062-0620529-0519 to Ž.G.

neuroprotection ; pathophysiology ; traumatic brain injury

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

53-54.

2019.

objavljeno

Podaci o matičnoj publikaciji

9. Hrvatski kongres farmakologije s međunarodnim sudjelovanjem - zbornik sažetaka

Zagreb: Hrvatsko društvo farmakologa

Podaci o skupu

9. hrvatski kongres farmakologije = 9th Croatian Congress of Pharmacology

pozvano predavanje

25.09.2019-28.09.2019

Zagreb, Hrvatska

Povezanost rada

Temeljne medicinske znanosti